Cancer microRNAs: From subtype profiling to predictors of response to therapy

Trends in Molecular Medicine

Volumn 17, Issue 5, 2011, Pages 235-243

  Chan, Elcie ^a   Prado, Daniel Estévez ^a,b   Weidhaas, Joanne Barnes ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER RISK; DISEASE ASSOCIATION; GENE EXPRESSION; GENE MUTATION; HUMAN; ONCOGENE; PHENOTYPE; PREDICTOR VARIABLE; PROGNOSIS; REVIEW;

GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS;

EID: 79955649353     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.01.008     Document Type: Review

References (106)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
3. Datta J., et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008, 68:5049-5058.
4. Lujambio A., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13556-13561.
5. Han L., et al. DNA methylation regulates MicroRNA expression. Cancer Biol. Ther. 2007, 6:1284-1288.
6. Calin G.A., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2999-3004.
7. Calin G.A., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15524-15529.
8. Zhang B., et al. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
9. Lu J., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
10. Volinia S., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2257-2261.
11. Liu C.G., et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9740-9744.
12. Margulies M., et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437:376-380.
13. Bennett S.T., et al. Toward the 1,000 dollars human genome. Pharmacogenomics 2005, 6:373-382.
14. Wang J., et al. TransmiR: a transcription factor-microRNA regulation database. Nucleic Acids Res. 2009, 38:D119-D122.
15. Drakaki A., Iliopoulos D. MicroRNA gene networks in oncogenesis. Curr. Genomics 2009, 10:35-41.
16. Liu A., et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int. J. Clin. Exp. Pathol. 2009, 2:519-527.
17. Jung M., et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin. Chem. 2010, 56:998-1006.
18. Murakami Y., et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537-2545.
19. Szczyrba J., et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol. Cancer Res. 2010, 8:529-538.
20. Liang Y., et al. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007, 8:166.
21. Rosenfeld N., et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 2008, 26:462-469.
22. Barroso-delJesus A., et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol. Cell. Biol. 2008, 28:6609-6619.
23. Ramaswamy S., et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:15149-15154.
24. Mitra R., et al. SFSSClass: an integrated approach for miRNA based tumor classification. BMC Bioinform. 2010, 11(Suppl. 1):S22.
25. Bandyopadhyay S., et al. Development of the human cancer microRNA network. Silence 2010, 1:6.
26. Zheng Y., Kwoh C.K. Informative microRNA expression patterns for cancer classification. Data Mining Biomed. Appl. 2006, 3916:143-154.
27. Oien K.A., Evans T.R. Raising the profile of cancer of unknown primary. J. Clin. Oncol. 2008, 26:4373-4375.
28. Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann. Oncol. 2003, 14(Suppl. 3):iii11-iii18.
29. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 2009, 360:790-800.
30. Sorlie T., et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127.
31. O'Day E., Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010, 12:201.
32. Du L., et al. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J. Exp. Clin. Cancer Res. 2010, 29:75.
33. Lebanony D., et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol. 2009, 27:2030-2037.
34. Petillo D., et al. MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol. 2009, 35:109-114.
35. Ueda T., et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11:136-146.
36. Fridman E., et al. Accurate molecular classification of renal tumors using microRNA expression. J. Mol. Diagn. 2010, 12:687-696.
37. Ratner E.S., et al. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol. Oncol. 2010, 118:251-257.
38. Blenkiron C., et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007, 8:R214.
39. Sempere L.F., et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67:11612-11620.
40. Mattie M.D., et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 2006, 5:24.
41. Lowery A.J., et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009, 11:R27.
42. Iorio M.V., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
43. Gregory P.A., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
44. Park S.M., et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22:894-907.
45. Baffa R., et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol. 2009, 219:214-221.
46. Uhlmann S., et al. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 2010, 29:4297-4306.
47. Sachdeva M., Mo Y.Y. miR-145-mediated suppression of cell growth, invasion and metastasis. Am. J. Transl. Res. 2010, 2:170-180.
48. Spizzo R., et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010, 17:246-254.
49. Sachdeva M., Mo Y.Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010, 70:378-387.
50. Calin G.A., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 353:1793-1801.
51. Garzon R., et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3945-3950.
52. Jongen-Lavrencic M., et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078-5085.
53. Garzon R., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
54. Marcucci G., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 2008, 358:1919-1928.
55. Dhillon A.S., et al. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
56. Caramuta S., et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol. 2010, 130:2062-2070.
57. Cahill S., et al. Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol. Cancer 2007, 6:21.
58. Lee C.H., et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS ONE 2009, 4:e7314.
59. Visone R., et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009, 114:3872-3879.
60. Gutierrez N.C., et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010, 24:629-637.
61. Chapiro E., et al. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia 2010, 24:1362-1364.
62. Adams J.M., et al. Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:1982-1986.
63. Robertus J.L., et al. MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br. J. Haematol. 2010, 149:896-899.
64. Gaur A., et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007, 67:2456-2468.
65. Marton S., et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 2008, 22:330-338.
66. Yanaihara N., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
67. Melo S.A., et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat. Genet. 2009, 41:365-370.
68. Kumar M.S., et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39:673-677.
69. Sevignani C., et al. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8017-8022.
70. Raveche E.S., et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007, 109:5079-5086.
71. Li W., et al. Germline mutation of microRNA-125a is associated with breast cancer. J. Med. Genet. 2009, 46:358-360.
72. Shen J., et al. Novel genetic variants in microRNA genes and familial breast cancer. Int. J. Cancer 2009, 124:1178-1182.
73. Shen J., et al. Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer 2010, 10:47.
74. Shen J., et al. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008, 29:1963-1966.
75. Yang R., et al. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res. Treat. 2009, 121:693-702.
76. Jazdzewski K., et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7269-7274.
77. Peng S., et al. Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig. Dis. Sci. 2009, 55:2288-2293.
78. Tian T., et al. A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1183-1187.
79. Hu Z., et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J. Clin. Invest. 2008, 118:2600-2608.
80. Xu B., et al. A functional polymorphism in Pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate 2010, 70:467-472.
81. Liu Z., et al. Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. Cancer 2010, 116:4753-4760.
82. Yang H., et al. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 2008, 68:2530-2537.
83. Ryan B.M., et al. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 2010, 10:389-402.
84. Pelletier C., Weidhaas J.B. MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev. Mol. Diagn. 2010, 10:817-829.
85. Nicoloso M.S., et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010, 70:2789-2798.
86. Chin L.J., et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008, 68:8535-8540.
87. Ratner E., et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010, 70:6509-6515.
88. Chen K., et al. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 2008, 29:1306-1311.
89. Medina P.P., et al. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
90. Li X., et al. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010, 59:579-585.
91. Ji J., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 2009, 361:1437-1447.
92. Rossi S., et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010, 116:945-952.
93. Dillhoff M., et al. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008, 12:2171-2176.
94. Schetter A.J., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
95. Zhou M., et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J. Biol. Chem. 2010, 285:21496-21507.
96. Giovannetti E., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70:4528-4538.
97. Ali A., et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606.
98. Yu J., et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol. Cancer 2010, 9:169.
99. Xu J.Z., Wong C.W. Hunting for robust gene signature from cancer profiling data: sources of variability, different interpretations, and recent methodological developments. Cancer Lett. 2010, 296:9-16.
100. Peltier H.J., Latham G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14:844-852.
101. Yu S.L., et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
102. Marsit C.J., et al. MicroRNA responses to cellular stress. Cancer Res. 2006, 66:10843-10848.
103. Kulshreshtha R., et al. A microRNA signature of hypoxia. Mol. Cell. Biol. 2007, 27:1859-1867.
104. Catucci I., et al. Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum. Mutat. 2010, 31:E1052-E1057.
105. Yazici H., et al. Investigation of the miR16-1 (C > T) + 7 substitution in seven different types of cancer from three ethnic groups. J. Oncol. 2009, 2009:827532.
106. Brierley K.L., et al. Errors in delivery of cancer genetics services: implications for practice. Conn. Med. 2010, 74:413-423.